Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07095933 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Mar 1, 2026 to Jul 1, 2026v5
  2. Start date: Nov 1, 2025 to Mar 1, 2026v4
  3. Start date: Sep 1, 2025 to Nov 1, 2025v3
  4. Start date: Aug 1, 2025 to Sep 1, 2025v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the clinical efficacy of everolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.
Trial Details
NCT Number NCT07095933
Lead Sponsor Xuanwu Hospital, Beijing
Conditions
(from sponsor)		 Epilepsy, Drug Resistant
Related terms Epilepsy
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov